AGR2在肺癌中的高表达预示着较差的生存率。

High expression of AGR2 in lung cancer is predictive of poor survival.

作者信息

Alavi Mohammed, Mah Vei, Maresh Erin L, Bagryanova Lora, Horvath Steve, Chia David, Goodglick Lee, Liu Alvin Y

机构信息

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, 10833 Le Conte Ave., Los Angeles, CA, 90095, USA.

Department of Statistics, David Geffen School of Medicine, University of California, Los Angeles, 10833 Le Conte Ave., Los Angeles, CA, 90095, USA.

出版信息

BMC Cancer. 2015 Oct 6;15:655. doi: 10.1186/s12885-015-1658-2.

BACKGROUND

Anterior gradient 2 (AGR2) is a protein disulfide isomerase-like protein widely expressed in many normal tissues as well as cancers. In our study, non-neoplastic bronchial epithelial cells as well as non-small cell lung cancer (NSCLC) cells express AGR2 protein.

METHODS

AGR2 expression was analyzed on lung tissue microarrays. Tumor staining was correlated with clinical outcomes.

RESULTS

On a lung cancer tissue microarray using immunohistochemistry, expression levels in cancer showed generally decreasing intensities in order from adenocarcinomas with mucinous components, other adenocarcinomas, squamous carcinomas, to large cell carcinomas. The study cohort was comprised of 400 cases. As a group, there was a slight trend of lower expression with increasing tumor grade. AGR2 expression level was a significant predictor of overall survival in younger patients only. Patients under 65 with lower levels showed a significantly better survival for both men and women. Patients over 65, in contrast, showed no such trend.

CONCLUSIONS

Nearly all NSCLC tumors show AGR2 expression. Lung cancer expression of AGR2 has prognostic value for younger patients.

背景

前梯度2（AGR2）是一种蛋白质二硫键异构酶样蛋白，在许多正常组织以及癌症中广泛表达。在我们的研究中，非肿瘤性支气管上皮细胞以及非小细胞肺癌（NSCLC）细胞均表达AGR2蛋白。

方法

对肺组织微阵列进行AGR2表达分析。肿瘤染色与临床结果相关。

结果

在使用免疫组织化学的肺癌组织微阵列上，癌症中的表达水平通常按照以下顺序呈递减强度：具有黏液成分的腺癌、其他腺癌、鳞癌、到大细胞癌。研究队列由400例病例组成。作为一个整体，随着肿瘤分级增加，表达有轻微降低的趋势。AGR2表达水平仅是年轻患者总生存的显著预测指标。65岁以下且表达水平较低的患者，无论男性还是女性，其生存率均显著更高。相比之下，65岁以上的患者未显示出这种趋势。